(Q37022433)

17 August 2017

Intravenous cyclophosphamide pulse therapy in the treatment of systemic sclerosis-related interstitial lung disease: a long term study (English)

1 reference

interstitial lung disease

17 August 2017

1 reference

X Muñoz

7

0 references

author name string

C P Simeón-Aznar

1

1 reference

17 August 2017

V Fonollosa-Plá

2

1 reference

17 August 2017

C Tolosa-Vilella

3

1 reference

17 August 2017

A Selva-O Callaghan

4

1 reference

17 August 2017

R Solans-Laqué

5

1 reference

17 August 2017

E Palliza

6

1 reference

17 August 2017

M Vilardell-Tarrés

8

1 reference

17 August 2017

language of work or name

1 reference

15 May 2008

1 reference

The open respiratory medicine journal

17 August 2017

1 reference

17 August 2017

2

1 reference

17 August 2017

39-45

1 reference

Design and analysis of health products and services: An example at a specialized COPD unit

17 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2606648

Neglected respiratory toxicity caused by cancer therapy.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2606648

A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2606648

Cyclophosphamide versus placebo in scleroderma lung disease.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2606648

Cyclophosphamide reduces neutrophilic alveolitis in patients with scleroderma lung disease: a retrospective analysis of serial bronchoalveolar lavage investigations.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2606648

Intravenous cyclophosphamide therapy for systemic sclerosis. A single-center experience and review of the literature with pooled analysis of lung function test results

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2606648

Evaluation and management of alveolitis and interstitial lung disease in scleroderma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2606648

Interstitial lung disease in scleroderma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2606648

Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2606648

Spirometric reference values from a Mediterranean population

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2606648

Glossary of terms for CT of the lungs: recommendations of the Nomenclature Committee of the Fleischner Society.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2606648

Toward the operational identification of adverse drug reactions

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2606648

Combination of intravenous pulses of cyclophosphamide and methylprednizolone in patients with systemic sclerosis and interstitial lung disease.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2606648

Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2606648

The impact of coexisting connective tissue disease on survival in patients with fibrosing alveolitis

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2606648

Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2606648

Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2606648

Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis

4 September 2018

1 reference

12 December 2020

Nonspecific interstitial pneumonia and usual interstitial pneumonia: comparative appearances at and diagnostic accuracy of thin-section CT

1 reference

12 December 2020

Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease

1 reference

12 December 2020

Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis

1 reference

12 December 2020

Predictors of survival in systemic sclerosis (scleroderma)

1 reference

12 December 2020

Severe organ involvement in systemic sclerosis with diffuse scleroderma

1 reference

12 December 2020

A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease

1 reference

12 December 2020

Scleroderma (systemic sclerosis): classification, subsets and pathogenesis

1 reference

12 December 2020

American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS)

1 reference

12 December 2020

Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis

1 reference

12 December 2020

Mortality in systemic sclerosis (scleroderma)

1 reference

12 December 2020

Intravenous cyclophosphamide for interstitial lung disease associated to systemic sclerosis: results with an 18-month long protocol including a maintenance phase

1 reference

12 December 2020

Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma

1 reference

12 December 2020

10.2174/1874306400802010039

Identifiers

DOI

1 reference

17 August 2017

1 reference

17 August 2017

PubMed publication ID

19340324

1 reference